Mitosis is one of the most fundamental processes of life by which a mammalian cell divides into two daughter cells. Mitosis has been an attractive target for anticancer therapies since fast proliferation was identified as one of the hallmarks of cancer cells. Despite efforts into developing specific inhibitors for mitotic kinases and kinesins, very few drugs have shown the efficiency of microtubule targeting-agents in cancer cells with paclitaxel being the most successful. A deeper translational research accompanying clinical trials of anti-mitotic drugs will help in identifying potent biomarkers predictive for response. Here, we review the current knowledge of mitosis targeting agents that have been tested so far in the clinics.
CITATION STYLE
Olziersky, A. M., & Labidi-Galy, S. I. (2017). Clinical development of anti-mitotic drugs in cancer. In Advances in Experimental Medicine and Biology (Vol. 1002, pp. 125–152). Springer New York LLC. https://doi.org/10.1007/978-3-319-57127-0_6
Mendeley helps you to discover research relevant for your work.